Back to Authors

Channick, Richard

A5110115221 | I136199984

Mayo Clinic

Harvard University

Citations 3

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804783

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612

Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804609